Humanigen Revenue and Competitors
Estimated Revenue & Valuation
- Humanigen's estimated annual revenue is currently $1M per year.
- Humanigen's estimated revenue per employee is $84,000
Employee Data
- Humanigen has 12 Employees.
- Humanigen grew their employee count by -29% last year.
Humanigen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Controller | Reveal Email/Phone |
2 | Head & SVP, Asia-Pacific Region & Business Development | Reveal Email/Phone |
3 | VP Finance | Reveal Email/Phone |
4 | VP, Portfolio Strategy, Clinical, Medical and Scientific Affairs | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Chief Scientific Officer | Reveal Email/Phone |
7 | Chairman, CEO | Reveal Email/Phone |
Humanigen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.9M | 24 | 4% | $89.5M | N/A |
What Is Humanigen?
Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1M
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Humanigen News
That average ranking earns Humanigen Inc an Analyst Rating of 29, which is better than 29% of stocks based on data compiled by InvestorsObserver...
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective...
Humanigen's monoclonal antibody lenzilumab is safe and effective for treating hospitalized patients with COVID-19, the results of a phase 3...
Other Companies in Burlingame
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 12 | -14% | N/A |
#2 | $1.9M | 13 | 8% | N/A |
#3 | $1.2M | 14 | N/A | N/A |
#4 | $0.8M | 14 | -62% | $38.5M |
#5 | $2.4M | 15 | -17% | N/A |